Unchained Labs Unveils LEA 9 Software Making Workflows Easy
Image credit: Unchained Labs
Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, has now released its LEA 9 software, making Freeslate and Junior automation systems way more accessible.
LEA, short for Laboratory Execution and Analysis Software, controls Freeslate and Junior systems, executes biologics and chemistry workflow designs, integrates third-party tools, and keeps all the data in one place.
LEA 9 adds a step-by-step workflow tool called Design Creator into the mix. There’s no coding, scripting or messing around with protocols. Scientists just drag and drop their workflow steps into place and they’re good to go. Design Creator also double checks each step to make sure it’s doable, so newbie users don’t have to worry about screwing things up.
“Freeslate and Junior already help researchers wipe out major hassles from their toughest workflows,” said Taegen Clary, VP of Marketing at Unchained Labs. “Automation can be insanely complicated, and really nerve wracking for casual users. LEA 9 makes lab automation totally easy and approachable for anyone.”
This article has been republished from materials provided by Unchained Labs. Note: material may have been edited for length and content. For further information, please contact the cited source.
Inter-areal Balanced Amplification Enhances Signal Propagation in the BrainNews
Neuroscientists find that signal transmission in a large-scale model of the primate brain is robust under the condition in which area-to-area connections exhibit a “balance” between excitation and inhibition.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by NovartisNews
The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.READ MORE
Comments | 0 ADD COMMENT
Microbiome Futures: A Global Translational Roadmap
May 23 - May 23, 2018